RDD Blog » Roche

R&D Directions Insider

Personalized med prototype? Plexxikon discusses melanoma hopeful

Friday, March 4th, 2011

Plexxikon Inc., the small 45-person biotech in Northern California, made international news this week when big pharma Daiichi Sankyo, Japanâ€™s third-largest drugmaker, agreed to buy the company for as much as $935 million, enticed largely by Plexxikonâ€™s anticipated late-stage targeted drug, PLX4032, for advanced melanoma. By now, you likely know ...

Posted in cancer, clinical trials | No Comments »

Roche appoints head of discovery

Tuesday, February 22nd, 2011

Roche named Anirvan Ghosh, Ph.D., head of discovery for the companyâ€™s central nervous system and translational area, where he will oversee discovery research in the central nervous system discovery and translational area with an emphasis on disorders such as schizophrenia, neurodegeneration, treatment-resistant depression, and neurodevelopment disorders. Using a combination of cellular, ...

Posted in People on the move, drug discovery | No Comments »

Roche pipeline takes stage

Wednesday, March 17th, 2010

Top executives with the Swiss pharma giant, eager toÂ shiftÂ attentionÂ fromÂ aÂ series of recentÂ clinical-trial setbacks,Â willÂ be inÂ New York City tomorrow for the company's first investor conference since itsÂ buyout of Genentech.Â They are expected to emphasize theÂ potential created byÂ Roche's new biotech armÂ andÂ highlight severalÂ promisingÂ pipeline drugs, led byÂ Phase III blockbuster candidates dalcetrapib, aleglitazar, and RG1678.Â I will be on ...

Posted in Uncategorized, clinical trials | No Comments »

Roche eyes new talent for Jersey makeover

Wednesday, October 28th, 2009

Roche is looking for a few good cellular biologists. More than a few, to be exact. The pharma giant has launched an ambitious recruitment campaign to add research muscle to its transforming R&D campus in Nutley, N.J., the former site of Rocheâ€™s U.S. commercial operations, since whisked off to South ...

Posted in Uncategorized, drug discovery | No Comments »

Roche deciphers cells with high content screening

Thursday, July 2nd, 2009

While other pharmaceutical companies may be taking a wait-and-see approach, Roche Nutley Research has been moving forward in using digital technology for drug discovery for the past ten years. To help find and validate promising drug candidates, the high content work group at Roche has been deciphering the microscopic language ...

Posted in drug discovery | No Comments »

©2012 UBM Canon